CD274 and non-small cell lung carcinoma: At present, programmed death-ligand 1 (PD-L1) expression is mainly selected in clinical practice for NSCLC immunotherapy, which is mainly evaluated by tissue biopsy measures, such as immunohistochemistry (IHC) [170], and ICI efficacy is also achieved in PD-L1-negative tumors.